Biomedical subjects

Eray Caliskan

Publications and source records attributed to Eray Caliskan.

22 records · Page 2Linked to original sources

PubMed2003

Oral misoprostol for the third stage of labor: a randomized controlled trial.

OBJECTIVE: To compare oral misoprostol with conventional oxytocics in the management of the third stage of labor. In a controlled trial, 1574 women were randomized into four groups, as follows: Group 1 received intravenous infusion of oxytocin 10 IU plus oral misoprostol 400 micro g, followed by two doses of oral misoprostol 100 micro g 4 hours apart; group 2 received oral misoprostol 400 micro g, followed by two doses of oral misoprostol 100 micro g 4 hours apart; group 3 received intravenous infusion of oxytocin 10 IU; and group 4 received intravenous infusion of oxytocin 10 IU plus intramuscular administration of methylergonovine maleate (Methergine) 0.2 mg. The incidence of postpartum hemorrhage and decrease in hemoglobin concentration from before delivery to 24 hours postpartum were the main outcome measures. RESULTS: The primary outcome measures were similar in groups 2 and 3. The incidence of postpartum hemorrhage was 9% in group 2, compared with 3.2% in group 1 and 3.5% in group 4 (P <.01, and P =.01, respectively). There were no significant differences among the four groups regarding hemoglobin concentrations. Significantly more women needed additional oxytocin in group 2, when compared with group 4 (5.9% versus 2.2%; P =.01). The proportion of women requiring additional methylergonovine maleate was 4.8% in group 2, compared with 0.7% in group 1 and 1% in group 4 (P <.01 and P =.01, respectively). CONCLUSION: Oral misoprostol alone is as effective as oxytocin alone for the prevention of postpartum hemorrhage; it is less effective than oxytocin plus methylergonovine maleate and oral misoprostol plus oxytocin.

Administration, Oral↗

PubMed2002

Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome.

OBJECTIVE: To evaluate the effect of metformin therapy on hyperandrogenism, insulin resistance, cervical scores, ovulation, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome (PCOS). DESIGN: Prospective, randomized, double-blind, placebo-controlled study. SETTING: Infertility clinic of a tertiary referral center. PATIENT(S): Fifty-six women with clomiphene citrate-resistant PCOS. INTERVENTION(S): Two cycles of oral metformin therapy (850 mg, twice daily) in group I and placebo therapy (twice daily) in group II. Clomiphene citrate (100 mg/day) on cycle days 3-7 of the second cycle in both groups. MAIN OUTCOME MEASURE(S): Insulin, T, DHEAS, FSH, LH, body mass index (BMI), waist-to-hip ratio, endometrial thickness, cervical score, ovulation, and pregnancy rates in clomiphene-induced cycles after metformin therapy. RESULT(S): Metformin therapy resulted in a significant decrease in total T, LH level, LH/FSH ratio, insulin resistance, and mean BMI. No difference in waist-to-hip ratio, DHEAS level, and fasting insulin level was observed. Clomiphene citrate induction resulted in higher ovulation rates and thicker endometrium in the metformin group than in the placebo group. There was higher cumulative pregnancy rate in the metformin group; however, there was no significant difference in the pregnancy rate between the two groups. CONCLUSION(S): Metformin therapy not only decreases hyperandrogenism and insulin resistance but also improves ovulation rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with PCOS.

Adult↗

PubMed2002

Laparoscopic conservation of the ovaries in cases with massive ovarian oedema.

Two women, one 27 years old (case 1) and the other 20 years old (case 2), were evaluated due to right lower quadrant pain. The lactate dehydrogenase level was increased in case 1 and the dihydroepiandostrone level was increased in both cases. Preoperative transvaginal ultrasonography revealed solid masses, but the tumour markers were within normal limits. At laparoscopy, oedematous ovaries were diagnosed in both cases. Untwisting of the ovaries and laparoscopic wedge resection combined with frozen section analysis resulted in conservation of the ovaries in both cases. The patients are symptom-free after 1 year of follow-up.

Adult↗

PubMed2002

Recurrent pelvic hydatid cyst obstructing labor, with a concomitant hepatic primary. A case report.

BACKGROUND: Hydatid disease in pregnancy is a rare condition, with an incidence of 1/20,000 pregnancies. Although the female reproductive system is a rare site for hydatid disease, various obstetric and gynecologic presentations have been reported. CASE: A 31-year-old multipara was evaluated due to obstructed labor. Sonographic evaluation revealed an 18-cm hepatic and 15-cm pelvic hydatid cyst at 38 weeks of gestation. A healthy, 3,200-g infant was delivered by cesarean section. The cyst, originating in the right ovary and occupying the pouch of Douglas, was removed surgically. The hepatic cyst was decompressed via the percutaneous approach. The follow-up was uneventful. CONCLUSION: Hydatid disease should be considered in the differential diagnosis of adnexal masses in pregnancy. The percutaneous technique is a promising treatment option for hepatic cysts. Not only the diagnosis but also the treatment of hydatid disease is facilitated with currently available magnetic resonance imaging, computed tomography and ultrasonography.

Adult↗